Anlon Healthcare, a fast-growing pharmaceutical manufacturing company headquartered in Rajkot, Gujarat, has announced its much-awaited Initial Public Offering (IPO). The issue is set to attract strong investor interest, given India’s booming pharmaceutical sector and the company’s focus on pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs).
This guide provides a complete overview of the Anlon Healthcare IPO—from issue details and financial performance to strengths, risks, and reasons why investors are keeping a close watch.
About Anlon Healthcare
Anlon Healthcare is engaged in the manufacturing of pharmaceutical intermediates and APIs, the essential building blocks used in medicines such as tablets, syrups, and nutraceuticals.
The company operates a state-of-the-art manufacturing facility in Rajkot, which is accredited with:
- ISO 9001:2015
- GMP Certification
- WHO-GMP Certification
These certifications ensure strict compliance with global quality standards, making the company a reliable partner in the pharmaceutical supply chain.
Anlon Healthcare IPO: Key Details
| Feature | Details |
|---|---|
| IPO Type | Fresh Issue (No Offer for Sale) |
| Number of Shares | 1.4 crore equity shares |
| Price Band | ₹86 to ₹91 per share |
| Listing Exchanges | BSE & NSE |
| Issue Method | 100% Book Building |
| Lead Manager | Interactive Financial Services Limited |
| Registrar | KFin Technologies |
| Use of Proceeds | Facility expansion, working capital, debt repayment, general corporate purposes |
💡 Why is Anlon Healthcare Launching an IPO?
The company aims to raise capital for:
- Manufacturing Expansion: ~₹30.7 crore for enhancing production capacity.
- Working Capital Needs: ~₹43.15 crore to strengthen day-to-day operations.
- Debt Repayment: ₹5 crore for reducing liabilities.
- Corporate Growth: Remaining proceeds for business development.
Financial Performance Snapshot
| Financial Metric | FY 2023-24 | FY 2022-23 | 10 Months Ending Jan 2025 |
|---|---|---|---|
| Revenue | ₹66.6 crore | ₹112.9 crore | ₹77.2 crore |
| Net Profit | ₹9.65 crore | ₹5.82 crore | ₹12 crore |
✅ Despite a dip in FY 2023-24 revenue, the company reported higher profits and strong revenue recovery in early 2025, reflecting operational efficiency and improving demand.
🚀 Strengths of Anlon Healthcare
- Global-Standard Quality: Backed by ISO, GMP, and WHO-GMP certifications.
- Experienced Promoters: Strong leadership with domain expertise in pharmaceuticals.
- Regulated Industry: High entry barriers due to stringent compliance requirements.
- Diverse Product Portfolio: Wide range of pharma intermediates and APIs.
Risks Investors Should Know
- Single Manufacturing Facility: Dependency on Rajkot unit increases operational risk.
- Customer Concentration: Revenue heavily reliant on a few clients.
- Competitive Market: Faces competition from well-established pharma manufacturers.
How to Apply for the Anlon Healthcare IPO?
Investors can apply using the ASBA (Application Supported by Blocked Amount) process via:
- Net banking (through registered banks)
- UPI-enabled broker apps & platforms
The shares will be allocated among:
- Retail Investors
- High Net-Worth Individuals (HNIs)
- Institutional Investors
Should You Invest in the Anlon Healthcare IPO?
The Anlon Healthcare IPO gives investors exposure to India’s rapidly expanding pharmaceutical manufacturing sector. With capacity expansion plans, improved profitability, and strong compliance standards, the company is well-positioned for growth.
However, risks such as client concentration and operational dependence on a single facility should be considered before investing.
Conclusion
The Anlon Healthcare IPO 2025 stands out as a promising opportunity for investors looking to diversify into the pharmaceutical sector. With solid financials, expansion-driven growth, and a strong regulatory track record, it has the potential to deliver long-term value.
👉 Stay updated on allotment status, subscription figures, and listing updates through official sources like KFin Technologies and Interactive Financial Services Limited.